leukemia

[Blood] Scientists found STAT5B to be specifically activated in HSCs and leukemic stem cells, where it induced many genes associated with quiescence and self-renewal, including the surface marker CD9.

[Leukemia] Researchers presented a strategy to target mutated JAK2 for degradation, using the cell’s intracellular degradation machinery, while sparing non-mutated JAK2, and found that targeting JOSD1 led to the death of JAK2-V617F-positive primary acute myeloid leukemia cells.

[Leukemia] The authors found that the RNA-binding protein IGF2BP3, which was overexpressed in mixed-lineage leukemia (MLL)-translocated leukemia, strongly amplified MLL-Af4-mediated leukemogenesis.

[Cell Death Discovery] The authors screened compounds inhibiting breast cancer cell proliferation with hematopoietic PBX-interacting protein (HPIP) fused with green fluorescent protein as a reporter. A novel agent named TXX-1-10 derived from rimonabant was discovered to reduce HPIP expression and had greater inhibitory effects on breast cancer cell growth and metastasis in vitro and in vivo than rimonabant.

[Cancer Chemotherapy and Pharmacology] The L-Arginine (Arg) auxotrophic cancerous cells like hepatocellular carcinoma, human colon cancer, leukemia, and breast cancer cells were sensitive to Arg depriving enzymes treatment due to low expression of crucial enzymes argininosuccinate synthetase, argininosuccinate lyase, and ornithine transcarbamylase.

[Blood Advances] This Phase II open-label study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myelogenous leukemia (CML) met its coprimary end points, showing sustained nilotinib efficacy in patients with newly diagnosed or imatinib/dasatinib resistant/intolerant CML.